Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9204222 | 0.94 | LMNA (0.53) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9202853 | 0.91 | HTT (0.55) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13853971 | 0.91 | HTT (0.58) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL1442202 | 0.88 | LMNA (0.56) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL1440479 | 0.88 | LMNA (0.56) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL7282990 | 0.87 | HSD17B10 (0.56) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13854151 | 0.85 | HTT (0.54) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13725441 | 0.84 | HTT (0.59) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL10251350 | 0.83 | LMNA (0.50) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13538300 | 0.83 | L3MBTL1 (0.50) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143038-B1 | PEPTIDE-NUCLEIC ACID-MONOMERS AND -OLIGOMERS | UGISENSE AG (DE) | 2018-08-01 | — | — | EP | disclosed |
| EP-2507249-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2507249-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8765722-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765722-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8501714-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501714-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2507249-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011031669-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031669-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | LMNA 1554/4885SMN1; SMN2 1851/4885HTT 4622/4885 |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | LMNA 1554/4885SMN1; SMN2 1851/4885HTT 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.